October 19, 2010 — CardioGen-82 (Rubidium Rb 82 Generator) when used with positron emission tomography (PET) myocardial perfusion imaging (MPI) has been shown to produce “reasonably low radiation exposure” of 3.7mSv for a complete rest/stress study. 1

Confirmed in the recently published study “Human Biodistribution and Radiation Dosimetry of 82Rb,” led by Frank Bengel, M.D., of Johns Hopkins University and featured in the October issue of Journal of Nuclear Medicine, this finding is added testament to the enhanced diagnostic ability and safety of this PET myocardial perfusion tracer.

“As the number of cardiovascular imaging procedures continues to increase, the concerns over radiation exposure have become an important issue. Our study provides scientific evidence for this discussion,” Bengel said. “It resolves a discrepancy between previously available estimates of radiation dose from rubidium-82. It confirms that rubidium-82 PET is at the lower end of radiation dose among cardiac imaging procedures involving ionizing radiation.”

Bengel evaluated 10 healthy volunteers who underwent dynamic PET/computed tomography (CT) — six contiguous table positions, each with separate 82Rb infusion. Source organ volumes of interest were delineated on the CT images and transferred to the PET images to obtain time-integrated activity coefficients. From the study, Dr. Bengel concluded that the current 82Rb dosimetry suggests reasonably low radiation exposure. On the basis of this study, a clinical 82Rb injection of 2 . 1,480 MBq (80 mCi) would result in a mean effective dose of 3.7 mSv using the weighting factors of the ICRP 103 – only slightly above the average annual natural background exposure in the United States (3.1 mSv). 1

Reference:
1. Bengel et al. Human Biodistribution and Radiation Dosimetry of 82Rb. Journal of Nuclear Medicine. 2010.

For more information: www.braccoimaging.com


Related Content

News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Radiology Imaging

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
arrow
News | Radiation Oncology

May 10, 2024 — Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical ...

Time May 10, 2024
arrow
News | Radiopharmaceuticals and Tracers

May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 08, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | Radiation Therapy

May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...

Time May 01, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
Subscribe Now